Computer-aided (in silico) approaches in the mode-of-action analysis and safety assessment of Ostarine and 4-methylamphetamine

Human Psychopharmacology

Volumn 28, Issue 4, 2013, Pages 365-378

  Mohd Fauzi, Fazlin ^a,b   Koutsoukas, Alexios ^a   Cunningham, Andrew ^c   Gallegos, Ana ^c   Sedefov, Roumen ^c   Bender, Andreas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

4 methylamphetamine; amphetamine; in silico target prediction; new psychoactive substances; Ostarine

Indexed keywords

4 METHYLAMPHETAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANDROGEN RECEPTOR; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE III; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; CATHEPSIN S; CHEMOKINE RECEPTOR CXCR3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOBOSARM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MELANIN CONCENTRATING HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 2; MICROSOMAL AMINOPEPTIDASE; MINERALOCORTICOID RECEPTOR; PROSTAGLANDIN E SYNTHASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN TYROSINE KINASE; SEROTONIN TRANSPORTER; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

AUTONOMIC DYSFUNCTION; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CHEMICAL STRUCTURE; COMPUTER ANALYSIS; CONFERENCE PAPER; DATA BASE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; HYPERTHERMIA; LEARNING ALGORITHM; MENTAL HEALTH; MOLECULAR WEIGHT; MUSCLE TONE; NEUROTOXICITY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; SEROTONIN SYNDROME; SURFACE PROPERTY;

4-METHYLAMPHETAMINE; AMPHETAMINE; IN SILICO TARGET PREDICTION; NEW PSYCHOACTIVE SUBSTANCES; OSTARINE;

AMIDES; ARTIFICIAL INTELLIGENCE; COMPUTER SIMULATION; HUMANS; METHAMPHETAMINE;

EID: 84880771469     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2322     Document Type: Conference Paper

References (117)

1. Abi-Dargham A, Van De Giessen E, Slifstein M, Kegeles LS, Laruelle M,. 2009. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65: 1091-1093.
2. Accelrys. Pipeline pilot [Online]. San Diego. Available: http://www.scitegic.com [Accessed 1 December 2011 ].
3. Alves E, Summavielle T, Alves CJ, et al,. 2009. Preclinical study: ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A. Addict Biol 14: 185-193.
4. Archer SL, Djaballah K, Humbert M, et al,. 1998. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 158; 1061-1067.
5. Barnett DH, Sheng S, Howe Charn T, et al,. 2008. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res 68: 3505-3515.
6. Baumann MH, Clark RD, Rothman RB,. 2008. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90: 208-217.
7. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB,. 2011. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
8. Bender A,. 2010. Databases: compound bioactivities go public. Nat Chem Biol 6: 309-309.
9. Bronstein DM, Hong JS,. 1995. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J Pharmacol Exp Ther 274: 943-950.
10. Brunton LL, Blumenthal DK, Buxton ILO, Parker KL,. 2008. Goodman & Gilman's Manual of Pharmacology and Therapeutics. United State of America: McGraw-Hill.
11. Buckholtz JW, Treadway MT, Cowan RL, et al,. 2010. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci 13: 419-421.
12. Camí J, Farré M,. 2003. Drug addiction. N Engl J Med 349: 975-986.
13. Carhart-Harris RL, King LA, Nutt DJ,. 2011. A web-based survey on mephedrone. Drug Alcohol Depend 118: 19-22.
14. Carson P, Oldroyd K, Phadke K,. 1987. Myocardial infarction due to amphetamine. Br Med J 294: 1525-1526.
15. Chang L, Ernst T, Grob C, Poland R,. 1999. Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J Magn Reson Imaging 10: 521-526.
16. Clark DE,. 2003. In silico prediction of blood-brain barrier permeation. Drug Discov Today 8: 927-933.
17. Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F,. 2000. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 24: 955-977.
18. Deeugenio D, Henn D,. 2004. Diet pills. In Drugs: The Straight Facts, Triggle D. J., (ed.). Infobase Publishing: New York.
19. Devlin RJ, Henry JA,. 2008. Clinical review: major consequences of illicit drug consumption. Crit Care 12: 202.
20. Di Chiara G, Imperato A,. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 85: 5274-5278.
21. Di Giovanni G, Di Matteo V, Esposito E,. 2002. Serotonin/dopamine interaction-focus on 5-HT2C receptor, a new target of psychotropic drugs. Indian J Exp Biol 40: 1344.
22. Emcdda-Europol. 2011. Annual report on the implementation of Council Decision 2005/387/JHA.
23. 1H MRS study. Neurology 54: 1344-1349.
24. Esposito E, Di Matteo V, Di Giovanni G,. 2008. Serotonin-dopamine interaction: an overview. Prog Brain Res 172: 3-6.
25. Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV,. 1998. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res 806: 1-7.
26. Fuller PJ, Young MJ,. 2005. Mechanisms of mineralocorticoid action. Hypertension 46: 1227-1235.
27. Gallegos A, Sedefov R,. 2011. Report on the Risk Assessment of Mephedrone in the Framework of the Council Decision on New Psychoactive Substances. EMCDDA: Lisbon.
28. Ganetsky M, Brush DE,. 2005. Serotonin syndrome-what have we learned? Clin Pediatric Emergency Med 6: 103-108.
29. Gaulton A, Bellis LJ, Bento AP, et al,. 2012. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-D1107.
30. Green AL, EI Hait MA,. 1980. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol 32: 262-266.
31. Green AR, Mechan AO, Elliott JM, O'shea E, Colado MI,. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
32. Greene SL, Kerr F, Braitberg G,. 2008. Review article: amphetamines and related drugs of abuse. Emerg Med Australas 20: 391-402.
33. Hadlock GC, Webb KM, Mcfadden LM, et al,. 2011. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
34. Hall AP, Henry JA,. 2006. Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 96: 678-685.
35. Hall FS, Li XF, Sora I, et al,. 2002. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 115: 153-161.
36. Heinlein CA, Chang C,. 2002. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187.
37. Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB,. 2009. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 190: 22.
38. Hert J, Willett P, Wilton DJ, et al,. 2004. Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. J Chem Inf Comput Sci 44: 1177-1185.
39. Hewton R, Salem A, Irvine RJ,. 2007. Potentiation of 3,4- methylenedioxymethamphetamine induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor. Clin Exp Pharmacol Physiol 34: 1051-1057.
40. Hirata H, Cadet JL,. 1997. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 69: 780-790.
41. Hla T, Brinkmann V,. 2011. Physiology and the effects of S1P receptor modulation. Neurology 76: S3-S8.
42. Itzhak Y, Achat-Mendes C,. 2004. Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'. IUBMB Life 56: 249-255.
43. Itzhak Y, Achat-Mendes CN, Ali SF, Anderson KL,. 2004. Long-lasting behavioral sensitization to psychostimulants following p-chloroamphetamine- induced neurotoxicity in mice. Neuropharmacology 46: 74-84.
44. Itzhak Y, Ali S, Achat C, Anderson K,. 2003a. Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice. Psychopharmacology (Berl) 166: 241-248.
45. Itzhak Y, Ali SF,. 2006. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol Ther 109: 246-262.
46. Itzhak Y, Ali SF, Anderson KL,. 2003b. Fenfluramine-induced serotonergic neurotoxicity in mice: lack of neuroprotection by inhibition/ablation of nNOS. J Neurochem 87: 268-271.
47. Kalant H,. 2001. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can Med Assoc J 165: 917-928.
48. Kauer JA, Malenka RC,. 2007. Synaptic plasticity and addiction. Nat Rev Neurosci 8: 844-858.
49. Kawashima S, Yokoyama M,. 2004. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24: 998-1005.
50. Kaye WH, Frank GK, Bailer UF, et al,. 2005. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav 85: 73-81.
51. Kehr J, Ichinose F, Yoshitake S, et al,. 2011. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
52. Kopnisky KL, Hyman SE,. 2002. Molecular and cellular biology of addiction. Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, Lippincott/Williams & Wilkins, Philadelphia.
53. Koutsoukas A, Lowe R, Kalantar-Motamedi Y, et al,. 2013. In silico target predictions: comparing multiclass Naïve Bayes and Parzen-Rosenblatt Window and the definition of a benchmarking dataset for target prediction. J Chem Inf Model (in revision).
54. Leonardi ETK, Azmitia EC,. 1994. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine. Neuropsychopharmacology 10: 231-238.
55. Lowe R, Mussa H, Nigsch F, Glen R, Mitchell J,. 2012. Predicting the mechanism of phospholipidosis. J Cheminformatics 4: 2-10.
56. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AGA,. 2011. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int 206: e93-e95.
57. Lyles J, Cadet JL,. 2003. Methylenedioxymethamphetamine (MDMA, ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Rev 42: 155-168.
58. Manchanda S, Connolly MJ,. 1993. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 69: 874-875.
59. Masaki T, Okada M, Tokuda M, et al,. 1999. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 29: 379-384.
60. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ,. 2011. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35: 188-191.
61. Mccann UD, Ricaurte GA,. 2004. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27: 821-826.
62. Mccann UD, Ridenour A, Shaham Y, Ricaurte GA,. 1994. Serotonin neurotoxicity after (+/-) 3, 4-methylenedroxymethamphetamine (MDMA; "ecstasy"): a controlled study in humans. Neuropsychopharmacology 10: 129-138.
63. Mcketin R, Mclaren J, Lubman DI, Hides L,. 2006. The prevalence of psychotic symptoms among methamphetamine users. Addiction 101: 1473-1478.
64. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang S-C, Phelps ME,. 1997. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766: 113-120.
65. Mohler ML, Bohl CE, Jones A, et al,. 2009. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 52: 3597-3617.
66. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'hearn E, Wilson MA,. 1990. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600: 640-661.
67. Morales-Mulia M, De Gortari P, Amaya M-I, Méndez M,. 2013. Acute ethanol administration differentially alters enkephalinase and aminopeptidase N activity and mRNA levels in regions of the nigrostriatal pathway. J Mol Neurosci 49: 289-300.
68. Mueller PD, Korey WS,. 1998. Death by "ecstasy": the serotonin syndrome? Ann Emerg Med 32: 377-380.
69. Müller CP, Carey RJ, Huston JP, De Souza Silva MA,. 2007. Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol 81: 133-178.
70. Murakami M, Nakatani Y, Tanioka T, Kudo I,. 2002. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68-69: 383-399.
71. Oxenkrug GF,. 2010. Tryptophan-kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 47: 56-63.
72. Parrott AC,. 2002. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71: 837-844.
73. Petitti DB, Sidney S, Quesenberry C, Bernstein A,. 1998. Stroke and cocaine or amphetamine use. Epidemiology 9: 596-600.
74. Prosser JM, Nelson LS,. 2012. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8: 33-42.
75. Qin S, Rottman JB, Myers P, et al,. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754.
76. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G,. 2012. Rang & Dale's Pharmacology, Churchill Livingstone. 4: 2-10.
77. Ritz MC, Kuhar MJ,. 1989. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 248: 1010-1017.
78. Rogers D, Hahn M,. 2010. Extended-connectivity fingerprints. J Chem Inf Model 50: 742-754.
79. Rothman RB, Baumann MH, Savage JE, et al,. 2000. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841.
80. Rothman R, Blough B, Baumann M,. 2007. Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions. The AAPS Journal9: E1-E10.
81. Rothman RB, Blough BE, Woolverton WL, et al,. 2005. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313: 1361-1369.
82. Ruttenber AJ,. 1991. Stalking the elusive designer drugs: techniques for monitoring new problems in drug abuse. J Addict Dis 11: 71-87.
83. Sailer AW, Sano H, Zeng Z, et al,. 2001. Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci 98: 7564-7569.
84. Schifano F, Albanese A, Fergus S, et al,. 2011. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214: 593-602.
85. Schilt T, De Win ML, Koeter M, et al,. 2007. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry 64: 728-736.
86. Seiden LS, Sabol KE,. 1996. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 163: 251-276.
87. Semple DM, Ebmeier KP, Glabus MF, O'carroll RE, Johnstone EC,. 1999. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-9.
88. Shannon VR, Chanez P, Bousquet J, Holtzman MJ,. 1993. Histochemical evidence for induction of arachidonate 15-lipoxygenase in airway disease. Am J Respir Crit Care Med 147: 1024-1028.
89. Sheridan RP, Kearsley SK,. 2002. Why do we need so many chemical similarity search methods? Drug Discov Today 7: 903-911.
90. Shi GP, Webb AC, Foster KE, et al,. 1994. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269: 11530-6.
91. Silins E, Copeland J, Dillon P,. 2007. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust N Z J Psychiatry 41: 649-655.
92. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S,. 2004. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 89: 5245-5255.
93. Sladek R, Beatty B, Squire J, et al,. 1997. Chromosomal mapping of the human and murine orphan receptors ERRα (ESRRA) and ERRβ (ESRRB) and identification of a novel human ERRα-related pseudogene. Genomics 45: 320-326.
94. Sora I, Hall FS, Andrews AM, et al,. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci 98: 5300-5305.
95. Sprague JE, Johnson MP, Schmidt CJ, Nichols DE,. 1996. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem Pharmacol 52: 1271-1277.
96. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M,. 2003. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 6: 347-352.
97. Steinkellner T, Freissmuth M, Sitte HH, Montgomery T,. 2011. The ugly side of amphetamines: short- and long-term toxicity of 3, 4- methylenedioxymethamphetamine (MDMA,'ecstasy'), methamphetamine and d -amphetamine. Biol Chem 392: 103-115.
98. Stone TW, Darlington LG,. 2002. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1: 609-620.
99. Tang S, Bhatia B, Maldonado CJ, et al,. 2002. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277: 16189-16201.
100. Thevis M, Geyer H, Thomas A, Schänzer W,. 2011. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal 3: 331-336.
101. Thevis M, Geyer H, Kamber M, Schänzer W,. 2009. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal 1: 387-392.
102. Torrance H, Cooper G,. 2010. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202: e62-e63.
103. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F,. 2008. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer 8: 74.
104. Türeci Ö, Sahin U, Vollmar E, et al,. 1998. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 95: 7608-7613.
105. Van Oekelen D, Megens A, Meert T, Luyten WHML, Leysen JE,. 2003. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. J Neurochem 85: 1087-1100.
106. Vilches-Herrera M, Miranda-Sepúlveda J, Rebolledo-Fuentes M, et al,. 2009. Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem 17: 2452-2460.
107. Waksman J, Taylor RN, Bodor GS, Daly FFS, Jolliff HA, Dart RC,. 2001. Acute myocardial infarction associated with amphetamine use. Mayo Clinic proceedings. Mayo Clinic 76: 323-326.
108. RAS farnesyltransferase α subunit in TGF-β and activin signaling. Science 271: 1120-1122.
109. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL,. 2005. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313: 848-854.
110. Willett P,. 2006. Enhancing the effectiveness of ligand-based virtual screening using data fusion. QSAR Comb Sci 25: 1143-1152.
111. Wood D, Davies S, Puchnarewicz M, et al,. 2010a. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6: 327-330.
112. Wood DM, Davies S, Greene SL, et al,. 2010b. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 48: 924-927.
113. Yamawaki S, Lai H, Horita A,. 1983. Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. J Pharmacol Exp Ther 227: 383-388.
114. Yui K, Ishiguro T, Goto K, Ikemoto S,. 1997. Precipitating factors in spontaneous recurrence of methamphetamine psychosis. Psychopharmacology (Berl) 134: 303-308.
115. Yui K, Ishiguro T, Goto K, Ikemoto S,. 2000. Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis. Ann N Y Acad Sci 914: 292-302.
116. Zilbermint MF, Dobs AS,. 2009. Nonsteroidal selective androgen receptor modulator Ostarine™ in cancer cachexia. Future Oncol 5: 1211-1220.
117. Zolkowska D, Rothman RB, Baumann MH,. 2006. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 318: 604-610.